Protech Home Medical Corp (PTQ.CA) Forecast, Price Target & Analyst Ratings
TSX-V:PTQ
2.06
-0.11 (-5.07%)
Last: May 12, 2021, 04:01 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for Protech Home Medical Corp (PTQ.CA).
Forecast Snapshot
Consensus Price Target
$3.13
+ 51.84% Upside
Next Earnings Forecast
Release DateN/A
PeriodQ2 / 2021
EPS Estimate
Revenue Estimate28.294M
ChartMill Buy Consensus
94.20%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$3.13
Upside
+ 51.84%
From current price of $2.06 to mean target of $3.13, Based on 7 analyst forecasts
Low
$2.53
Median
$3.16
High
$3.68
Price Target Revisions
1 Month
N/A
3 Months
N/A
Price Target Summary
7 analysts have analysed PTQ.CA and the average price target is 3.13 null. This implies a price increase of 51.84% is expected in the next year compared to the current price of 2.06.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
94.20%
PTQ.CA was analyzed by 7 analysts. The buy percentage consensus is at 94. So analysts seem to be very confident about PTQ.CA.
In the previous month the buy percentage consensus was at a similar level.
PTQ.CA was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
Next Earnings Forecast Details
Next Earnings Details
Release DateN/A
PeriodQ2 / 2021
EPS EstimateN/A
Revenue Estimate28.294M
Revenue Q2Q16.04%
EPS Q2QN/A
Number of AnalystsN/A
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A 102.18% | N/A -6.90% | N/A -40.46% | N/A 12.96% | N/A 14.82% | N/A 16.72% | N/A 16.34% | N/A 19.79% | N/A 16.32% | N/A 18.07% | |
| EBITDA YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A -20.00% | N/A 133.33% | N/A -200.00% | N/A 88.00% | N/A 14.80% | N/A 279.15% | N/A 117.49% | N/A 75.72% | N/A 90.88% | N/A 96.61% |
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q2 / 21 | Q3 / 21 | Q4 / 21 | Q1 / 22 | Q2 / 22 | Q3 / 22 | Q4 / 22 | Q1 / 23 | Q2 / 23 | Q3 / 23 | Q4 / 23 | Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | N/A | N/A | N/A | 0.01 165.04% | 0.01 | 0.01 | 0.01 | 0.03 137.53% | 0.03 137.53% | 0.03 137.53% | 0.04 216.71% | 0.04 33.33% | 0.04 33.33% | 0.04 33.33% | 0.04 |
| Revenue Q2Q % growth | 28.294M 16.04% | 30.615M 20.91% | 33.046M 22.57% | 34.23M 14.34% | 35.603M 25.83% | 37.794M 23.45% | 38.163M 15.49% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
Protech Home Medical Corp / PTQ.CA Forecast FAQ
What do analysts expect the price target to be for Protech Home Medical Corp (PTQ.CA)?
7 analysts have analysed PTQ.CA and the average price target is 3.13 null. This implies a price increase of 51.84% is expected in the next year compared to the current price of 2.06.